Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.678922
Title: Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
Author: Jallad, Samer
ISNI:       0000 0004 5370 9726
Awarding Body: University of Brighton
Current Institution: University of Brighton
Date of Award: 2015
Availability of Full Text:
Access through EThOS:
Access through Institution:
Abstract:
Intravesical Bacillus Calmette–Guérin (BCG) immunotherapy is the main treatment for bladder high-grade non-muscle invasive transitional cell carcinoma (HGNMITCC) following initial resection. Unfortunately, about 30% of patients will not respond to treatment and they carry a high risk of disease progression. The alternative, radical cystectomy, has major risks with high morbidity and mortality. The ability to predict the response to BCG treatment would be a useful tool in the selection of appropriate treatment modalities. This study investigated a variety of detectable immune responses in blood and urine to establish if there were differences between responders and non-responders to BCG treatment. We evaluated whether there were detectable immunological differences in blood or urine that could explain or predict outcome.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.678922  DOI: Not available
Keywords: A000 Medicine
Share: